Primary structure of human skeletal growth factor: homology with human insulin-like growth factor-II.
Human skeletal growth factor (human SGF) extracted from human bone has been purified to homogeneity by hydroxyapatite chromatography and gel filtration under dissociative conditions followed by FPLC heparin-Sepharose affinity chromatography and reverse phase HPLC. Human SGF was homogeneous except that in each preparation about 30% of SGF molecules lacked the N-terminal alanine. 75% of the human SGF sequence has been determined. The amino acid sequences of the N-terminal 20 amino acids and of several tryptic fragments were identical to the corresponding sequences of human insulin-like growth factor-II (IGF-II) purified from serum. However, since the C-peptide (variable region) of human SGF has not yet been sequenced, we cannot conclude that SGF is identical to IGF-II. Comparison of the amino acid sequence of human SGF with that of IGF-II variants that have been described in the literature revealed that human SGF is not one of the known IGF-II variants. IGF-I was also found in human bone extract but was several-fold less abundant than SGF/IGF-II. The relative abundance of SGF/IGF-II and IGF-I in bone corresponded to the relative rates of production of these two mitogens by human bone cells in vitro. Regarding the physiological significance of IGF-II in bone, previous studies on the biological actions of SGF in vitro suggest that this growth factor can have both paracrine and autocrine functions on cells of the osteoblast line. In addition, we have proposed the concept that SGF is a mediator of the coupling of bone formation to bone resorption, an important bone volume regulatory mechanism. In as much as SGF is very similar (if not identical) to IGF-II, it seems likely that these proposed regulatory functions of SGF in bone are attributable to IGF-II.
Mohan
S
S
Department of Biochemistry, Loma Linda University, CA.
Jennings
J C
JC
Linkhart
T A
TA
Baylink
D J
DJ
D000595:Amino Acid Sequence; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002846:Chromatography, Affinity; D005270:Femur Head / Q000032:analysis; D006133:Growth Substances / Q000302:isolation & purification*; D006493:Heparin / Q000378:metabolism; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000032:analysis*; D008969:Molecular Sequence Data; D008970:Molecular Weight; D011506:Proteins / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology; D012689:Sequence Homology, Nucleic Acid; D013002:Somatomedins / Q000032:analysis*; D013936:Thymidine / Q000378:metabolism
D006133:Growth Substances; C035170:IGF2 protein, human; D011506:Proteins; D013002:Somatomedins; D007335:Insulin-Like Growth Factor II; D006493:Heparin; D013936:Thymidine